QUEBEC CITY, June 8 /CNW/ - Medicago Inc. (TSX-V:MDG) (the "Company"), a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that Mr. Andy Sheldon, President and CEO, presented at the World Vaccine Congress Asia 2009. The conference is being held at the Marina Mandarin, Singapore, from June 8-11, 2009.

Mr. Sheldon's presentation, entitled "Innovative H5N1 virus-like particles: a unique combination of product and manufacturing solutions", discussed how Medicago's plant-based Proficia(TM) manufacturing technology, a system that combined with the Company's VLP vaccine technology, could deliver a vaccine just one month after the identification of the genetic sequence from an emerging pandemic strain. Mr. Sheldon also reviewed the ongoing research and development of a H1N1 vaccine candidate. The Company recently disclosed that it successfully expressed a new VLP antigen ("H1 VLP") from the influenza A (H1N1) strain within 14 days of receiving the DNA sequence and is currently conducting a study in mice to determine the immunogenic potential of this new candidate.

World Vaccine Congress Asia 2009 is a meeting where vaccine buyers and sellers, health authorities, financing institutions, regulators, vaccine producers and manufacturers, technology providers and other stakeholders come together to discuss industry trend, market and partnership opportunities, new vaccines and new technology innovations across Asia.

About Medicago

Medicago is committed to provide highly effective and affordable vaccines based on proprietary Virus-Like Particle (VLP) and manufacturing technologies. Medicago is developing VLP vaccines to protect against H5N1 pandemic influenza, using a transient expression system which produces recombinant vaccine antigens in non-transgenic plants. This technology has potential to offer advantages of speed and cost over competitive technologies. It could deliver a vaccine for testing in about a month after the identification and reception of genetic sequences from a pandemic strain. This production time frame has the potential to allow vaccination of the population before the first wave of a pandemic strikes and to supply large volumes of vaccine antigens to the world market. Additional information about Medicago is available at www.medicago.com.

Forward-Looking Statements

This press release contains forward-looking statements which reflect Medicago's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. Medicago disclaims any obligation to update these forward-looking statements.

    <<
    Neither TSX Venture Exchange nor its Regulation Services Provider (as
    that term is defined in the policies of the TSX Venture Exchange) accepts
    responsibility for the adequacy or accuracy of this release
    >>

%SEDAR: 00023641E